The FDA's Approval of Gazyva for Follicular Lymphoma
Things to consider
One downside with Gazyva may be its cost; since it’s a new drug, there is no generic form yet available. (Rituxan, on the other hand, has been on the market for over 10-years, and comes in generic form.)
Perhaps the issue of the toxic effects from bendamustine may be of concern to you.
Also, the Rituxan researchers have some questions on the protocol and some study results related to Gazyva. (Medscape)
And, others have said “the competition between these agents looks too close to call.”